妊娠期癌症的免疫治疗
综述总结妊娠期使用免疫治疗的临床前与临床数据,涵盖已获批的免疫检查点抑制剂、重组细胞因子、细胞治疗、疫苗和免疫调节药物,讨论母体免疫适应与胎儿母体耐受机制可能被肿瘤劫持而影响妊娠。
要点
- 妊娠期母体免疫系统发生适应以维持对病原体防御并避免对半同种异体胎儿的损害。
- 肿瘤可劫持建立胎儿母体耐受的通路,靶向这些抑制通路的免疫治疗可能导致妊娠并发症。
- 免疫治疗激活患者免疫系统可发生广泛免疫相关不良事件,可能对胎儿产生负面影响或阻碍未来妊娠。
核心结论
- 随着免疫治疗适应证不断扩大,需更好理解这些治疗对妊娠和生育的影响。
研究设计与样本
- 本综述总结妊娠期使用免疫治疗的临床前和临床数据,包括所有已获批的免疫检查点抑制剂、重组细胞因子、细胞治疗、疫苗和免疫调节药物。
主要发现
- 妊娠期母体免疫系统发生显著适应以维持对病原体防御并避免对半同种异体胎儿的不良反应。
- 参与建立胎儿母体耐受的通路可被肿瘤劫持。
- 靶向这些抑制通路或直接与参与耐受机制的调节性免疫细胞相互作用的免疫治疗,可能导致妊娠期并发症。
- 通过免疫治疗激活患者免疫系统可发生广泛免疫相关不良事件,可能对胎儿产生负面影响或阻碍未来期望的妊娠。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immunotherapy has greatly improved outcomes for subgroups of patients with cancer. As indications keep expanding, there is an unmet need to gain a better understanding of the effect of these therapies on pregnancy and fertility. During pregnancy, substantial adaptations occur in the maternal immune system to maintain protection against pathogens while avoiding detrimental reactions to the semi-allogeneic fetus. The pathways involved in the establishment of this fetomaternal tolerance can be hijacked by cancers. Immunotherapies that target these inhibitory pathways, or that directly interact with the regulatory immune cells involved in tolerance mechanisms, might therefore result in complications during pregnancy. Similarly, by activating the patient's immune system with immunotherapy, a broad range of immune-related adverse events can occur that could negatively affect the fetus or impede a future desired pregnancy. This Review summarises preclinical and clinical data related to the use of immunotherapy during pregnancy, including all approved immune checkpoint inhibitors, recombinant cytokines, cell therapies, vaccines, and immunomodulatory drugs.
引用
- Borgers JSW, Heimovaara JH, Cardonick E, et al. Immunotherapy for cancer treatment during pregnancy. Lancet Oncol. 2021. PMID: 34856152. doi:10.1016/S1470-2045(21)00525-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。